CD4+ Lymphocyte cell enumeration for prediction of clinical course of human immunodeficiency virus disease: A review

Journal of Infectious Diseases

Volumn 165, Issue 2, 1992, Pages 352-363

  Stein, Daniel S ^a   Korvick, Joyce A ^a   Vermund, Sten H ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; DIDANOSINE; INTERFERON; RIBAVIRIN; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DISEASE COURSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; NOTE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIVIRAL AGENTS; CD4-CD8 RATIO; CD4-POSITIVE T-LYMPHOCYTES; HIV ANTIBODIES; HIV INFECTIONS; HUMAN; LEUKOCYTE COUNT; SUPPORT, U.S. GOV'T, P.H.S.; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 0026515551     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/165.2.352     Document Type: Article

References (78)

1. Popovic M, Sarngadharan MG. Read E, Gallo RC. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 1984;224:497-500.
2. Barre-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T-lympho-tropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;220:868-71.
3. + T cell depletion in AIDS. Cell 1988;54:441-4.
4. Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, Chen IS. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 1990;61:213-22.
5. Wilson CB. The cellular immune system and its role in host defense. In: Mandell GL. Douglas RG, Bennett JE, eds. Principles and practice of infectious diseases. 3rd ed. New York: Churchill Livingstone, 1990:101-38.
6. Fauci AS. The human immunodeficiency virus: infectivity and mechanisms of pathogenesis. Science 1988;239:617-22.
7. Chamberlain ME, Curran JW. Epidemiology and prevention of AIDS and HIV infection. In: Mandell DL, Douglas RL, Bennett JE, eds. Principles and practice of infectious diseases. 3rd ed. New York: Churchill-Livingstone, 1990.
8. Giorgi JV, Cheng HL, Margolick JB, et al. Quality control in the flow cytometric measurement of T-lymphocyte subsets: the Multicenter AIDS Cohort Study experience. Clin Immunol lmmunopathol 1990;55:173-86.
9. Kaslow RA, Ostrow DG, Detels R, Phair JP, Polk BF, Rinaldo CR. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol 1987;126:310-8.
10. + in patients infected with HIV. N Engl J Med 1988;319:581-2.
11. Taylor JM, Fahey JL, Detels R, Giorgi JV. CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: which to choose and how to use. J Acquir Immune Defic Syndr 1989;2:114-24.
12. Clark SJ, Saag MS, Decker WD, et al. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N Engl J Med 1991;324:954-60.
13. Daar ES, Moudgil T, Meyer RD. Ho DD. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med 1991;324:961-4.
14. Kessler HA, Blaauw B. Spear J, Paul DA, Falk LA, Landay A. Diagnosis of human immunodeficiency virus infection in seronegative homosexuals presenting with an acute viral syndrome. JAMA 1987;258:l 196-9.
15. Von Sydow M, Gaines H, Sonnerborg A, Forsgren M, Pehrson PO, Strannegard O. Antigen detection in primary HIV infection. BMJ 1988;296:238-40.
16. Nishanian P, Huskins KR, Stehn S, Detels R, Fahey JL. A simple method for improved assay demonstrates that HIV p24 antigen is present as immune complexes in most sera from HIV-infected individuals. J Infect Dis 1990;162:21-8.
17. Kageyama S, Yamada O, Mohammad SS, et al. An improved method for the detection of HIV antigen in the blood of carriers. J Virol Methods 1988;22:125-31.
18. Bernier GM. Beta 2-microglobulin: structure, function and significance. Vox Sang 1980;38:323-7.
19. Huber C, Batchelor JR. Fuchs D, et al. Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med 1984;160:310-6.
20. Hofmann B, Wang YX, Cumberland WG, Detels R, Bozorgmehri M, Fahey JL. Serum beta 2-microglobulin level increases in HIV infection: relation to seroconversion, CD4 T-cell fall and prognosis. AIDS 1990;4:207-14.
21. Melmed RN, Taylor JM, Detels R, Bozorgmehri M, Fahey JL. Serum neopterin changes in HIV-infected subjects: indicator of significant pathology, CD4 T cell changes, and the development of AIDS. J Acquir Immune Defic Syndr 1989;2:70-6.
22. ‒ lymphocytes. Clin Immunol lmmunopathol 1989;51:348-61.
23. + cell changes after HIV-1 infection indicate the existence of a codeterminant of AIDS. J Acquir Immune Defic Syndr 1988;1:390-5.
24. Lang W. Perkins H, Anderson RE, Royce R, Jewell N, Winkelstein W Jr. Patterns of T lymphocyte changes with human immunodeficiency virus infection: from seroconversion to the development of AIDS. J Acquir Immune Defic Syndr 1989;2:63-9.
25. + lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 1986;234:1563-6.
26. + T cell counts. J Infect Dis 1991;164:631-7.
27. + T-lymphocyte counts: preliminary results from the San Francisco Men's Health Study. AIDS 1990;4:327-33.
28. Moss AR, Bacchetti P, Osmond D, et al. Seropositivity for HIV and the development of AIDS or AIDS-related condition: three year follow up of the San Francisco General Hospital cohort. BMJ 1988;296:745-50.
29. 2-microglobulin are early predictors of acquired immunodeficiency syndrome. Monogr Virol 1990;18:61-73.
30. Goedert JJ, Kessler CM, Aledort LM, et al. A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N Engl J Med 1989;321:1141-8.
31. Donegan E, Stuart M, Niland JC, et al. Infection with human immunodeficiency virus type 1 (HIV-1) among recipients of antibody-positive blood donations. Ann Intern Med 1990;113:733-9.
32. Phillips AN, Lee CA, Hlford J, et al. Serial CD4 lymphocyte counts and development of AIDS. Lancet 1991;337:389-92.
33. Kaslow RA, Phair JP, Friedman HB, et al. Infection with the human immunodeficiency virus: clinical manifestations and their relationship to immune deficiency. A report from the Multicenter AIDS Cohort Study. Ann Intern Med 1987;107:474-80.
34. Polk BF, Fox R, Brookmeyer R, et al. Predictors of the acquired immunodeficiency syndrome developing in a cohort of seropositive homosexual men. N Engl J Med 1987;316:61-6.
35. + cellsand the levels of core antigens of and antibodies to the human immunodeficiency virus as predictors of AIDS among seropositive homosexual men. J Infect Dis 1988; 158:615-22.
36. Eyster ME, Ballard JO, Gail MH, Drummond JE, Goedert JJ. Predictive markers for the acquired immunodeficiency syndrome (AIDS) in hemophiliacs: persistence of p24 antigen and low T4 cell count. Ann Intern Med 1989;1 10:963-9.
37. Becherer PR, Smiley ML, Matthews TJ, Weinhold KJ, McMillan CW, White GC. Human immunodeficiency virus-1 disease progression in hemophiliacs. Am J Hematol 1990;34:204-9.
38. MacDonell KB, Chmiel JS, Poggensee L, Wu S, Phair JP. Predicting progression to AIDS: combined usefulness of CD4 lymphocyte counts and p24 antigenemia. Am J Med 1990;89:706-12.
39. Fahey JL, Taylor JM, Detels R, et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med 1990;322:166-72.
40. Anderson RE, Lang W, Shiboski S, Royce R, Jewell N, Winkelstein W Jr. Use of beta 2-microglobulin level and CD4 lymphocyte count to predict development of acquired immunodeficiency syndrome in persons with human immunodeficiency virus infection. Arch Intern Med 1990;150:73-7.
41. Hoy JF, Lewis DE, Miller GG. Functional versus phenotypic analysis of T cells in subjects seropositive for the human immunodeficiency virus: a prospective study of in vitro responses to Cryptococcus neoformans. J Infect Dis 1988;158:1071-8.
42. Masur H, Ognibene FP, Yarchoan R, et al. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection. Ann Intern Med 1989; 111:223-31.
43. Phair J, Muñoz A, Detels R, et al. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. N Engl J Med 1990;322:161-5.
44. Leoung GS, Feigal DW Jr. Montgomery AB. et al. Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia. The San Francisco community prophylaxis trial. N Engl J Med 1990:323:769-75.
45. Centers for Disease Control. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus. MMWR 1989;38(suppl 5): 1-9.
46. Vermund SH, Hoth DF. How can epidemiology assist in guiding interventions for the acquired immunodeficiency syndrome/human immunodeficiency virus. Ann Epidemiol 1990;1:141-55.
47. Hirschel B, Lazzarin A, Chopard P, et al. A controlled study of inhaled pentamidine for primary prevention of Pneumocystis carinii pneumonia. N Engl J Med 1991;324:1079-83.
48. Graham NM, Zeger SL, Kuo V, et al. Zidovudine use in AIDS-free HIV-1-seropositive homosexual men in the Multicenter AIDS Cohort Study (MACS), 1987-1989. J Acquir Immune Defic Syndr 1991;4:267-76.
49. Yarchoan R, Perno CF, Thomas RV, et al. Phase I studies of 2′, 3′-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet 1988;1:76-81.
50. Merigan TC, Skowron G, Bozzette SA, et al. Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections: a phase I and II study. Ann Intern Med 1989;110:189-94.
51. Lane HC, Davey V, Kovacs JA, et al. Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection: a randomized, placebo-controlled trial. Ann Intern Med 1990; 112:805-11.
52. Roberts RB, Jurica K, Meyer WA III, Paxton H, Makuch RW. A phase 1 study of ribavirin in human immunodeficiency virus-infected patients. J Infect Dis 1990;162:638-42.
53. Roberts RB, Hollinger FB. Parks WP, et al. A multicenter clinical trial of oral ribavirin in HIV-infected people with lymphadenopathy: viro-Iogic observations. AIDS 1990;4:67-72.
54. Crumpacker C, Heagy W, Bubley G, et al. Ribavirin treatment of the acquired immunodeficiency syndrome (AIDS) and the acquired-immunodeficiency-syndrome-related complex (ARC): a phase 1 study shows transient clinical improvement associated with suppression of the human immunodeficiency virus and enhanced lymphocyte proliferation. Ann Intern Med 1987;107:664-74.
55. Spanish Ribavirin Trial Group. Comparison of ribavirin and placebo in CDC group III human immunodeficiency virus infection. Lancet 1991;338:6-9.
56. Pedersen C, Sandstrom E, Petersen CS, et al. The efficacy of inosine pranobex in preventing the acquired immunodeficiency syndrome in patients with human immunodeficiency virus infection. N Engl J Med 1990;322:1757-63.
57. Lang JM, Touraine JL, Trepo C, et al. Randomised, double-blind, placebo-controlled trial of ditiocarb sodium ('imuthiol') in human immunodeficiency virus infection. Lancet 1988;2:702-6.
58. Hersh EM, Brewton G, Abrams D, et al. Ditiocarb sodium (diethyldith-iocarbamate) therapy in patients with symptomatic HIV infection and AIDS. A randomized, double-blind, placebo-controlled, multicenter study. JAMA 1991;265:1538-44.
59. Abrams DI, Kuno S, Wong R, et al. Oral dextran sulfate (UA001) in the treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Ann Intern Med 1989; 110:183-8.
60. Yarchoan R, Klecker RW. Weinhold KJ, et al. Administration of 3′-azido-3′-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet 1986;1:575-80.
61. Collier AC. Bozzette S, Coombs RW, et al. A pilot study of low-dose zidovudine in human immunodeficiency virus infection. N Engl J Med 1990;323:1015-21.
62. Cooper DA, Pedersen C, Aiuti F, et al. The efficacy and safety of zidovudine with or without acyclovir in the treatment of patients with AIDS-related complex. AIDS 1991;5:933-44.
63. Fischi MA, Richman DD, Grieco MH, et al. The efficacy of azidothy-midine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987;317:185-91.
64. Fischi MA, Richman DD, Causey DM, et al. Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. JAMA 1989;262:2405-10.
65. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection. N Engl J Med 1990;322:941-9.
66. Fischi MA, Richman DD, Hansen N, et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection: a double-blind. placebo-controlled trial. Ann Intern Med 1990; 112:727-37.
67. Fischi MA, Parker CB, Pettinelii C, et al. A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. N Engl J Med 1990;323:1009-14.
68. Lambert JS, Seidlin M, Reichman RC, et al. 2′, 3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial. N Engl J Med 1990;322:1333-40.
69. Cooley TP, Kunches LM, Saunders CA, et al. Once-daily administration of 2′, 3′-dideoxyinosine (ddl) in patients with the acquired immu-nodeficiency syndrome or AIDS-related complex. Results of a phase I trial. N Engl J Med 1990;322:1340-5.
70. Friedman LM, Jurberg CD, DeMets DL. Fundamentals of clinical trials. 2nd ed. Littleton, MA: PSG Publishing, 1985:112-7.
71. Rinaldo C, Huang XL, Piazza P. et al. Augmentation of cellular immune function during the early phase of zidovudine treatment of AIDS patients. J Infect Dis 1991;164:638-45.
72. Moore RD, Hidalgo J, Sugland BW, Chaisson RE. Zidovudine and the natural history of the acquired immunodeficiency syndrome. N Engl J Med 1991;324:1412-6.
73. Jacobson MA, Bacchetti P, Kolokathis A, et al. Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine. BMJ 1991;302:73-8.
74. Ellenberg SS. Surrogate end points in clinical trials. BMJ 1991; 302:63-4.
75. Gail MH, Rosenberg PS, Goedert JJ. Therapy may explain recent deficits in AIDS incidence. J Acquir Immune Defic Syndr 1990;3:296-306.
76. Rosenberg PS, Gail MH, Schrager LK, et al. National AIDS incidence trends and the extent of zidovudine therapy in selected demographic and transmission groups. J Acquir Immune Defic Syndr 1991;4:392-401.
77. Graham NMH, Zeger SL, Park LP, et al. Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS. Lancet 1991;338:265-9.
78. Brookmeyer R. Reconstruction and future trends of the AIDS epidemic in the United States. Science 1991;253:37-42.